USPatentGranted
B2Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
Granted 31 Dec 2013 · 2 office actions
Assignee: HANALL BIOPHARMA CO., LTD.
Law firm: Law firm · Log in to unlock
Attorney: Attorney · Log in to unlock
Inventors: Yeon Jung Song, Jae Kap Jeong, Seung Kook Park, Sung Wuk Kim +4 · Examiner: Schuyler Milton
Application
13/513,803
filed 21 Dec 2011
Publication
US 20120277142
published 1 Nov 2012
Patent· this page
US 8,618,045
granted 31 Dec 2013
23
Claims
1 independent
88
File wrapper
transactions
2031
20-year term
term adjustment not held
none
Litigation
checked
38
Classifications
A61P1/00, A61P25/08
9
Citations
9 cites · 0 cited by
Life of the patent
12 dated events⤢ drag to zoom
ProsecutionTerm & feeshover for detail · click to open
Abstract
Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases.
Claims
23 · 1 independent · depth 523 granted claims
›1.independentA modified tumor necrosis factor receptor-1 polypeptide, comprising an amino acid sequence selected from the group consisting of:nan amino acid sequen…+22
›2.↳ 1The modified tumor necrosis factor receptor-1 polypeptide of claim 1, comprising an amino acid sequence selected from the group consisting of:nan amin…d2+2
›3.↳ 2The modified tumor necrosis factor receptor-1 polypeptide of claim 2,nwherein the amino acid sequence based on the amino acid sequence of a wild-type …d3+1
›8.↳ 3The modified tumor necrosis factor receptor-1 polypeptide of claim 3, comprising an amino acid modification selected from the group consisting of L68V…d4
›4.↳ 1The modified tumor necrosis factor receptor-1 polypeptide of claim 1, wherein amino acid residues are modified in such a way that:nL at position 68 is…d2+1
›5.↳ 4The modified tumor necrosis factor receptor-1 polypeptide of claim 4, whereinnS at position 92 is substituted with I, M or H; andR at position 97 is s…d3
›6.↳ 1The modified tumor necrosis factor receptor-1 polypeptide of claim 1,nwherein the amino acid sequence based on the amino acid sequence of a wild-type …d2+1
›9.↳ 6The modified tumor necrosis factor receptor-1 polypeptide of claim 6, comprising an amino acid modification of L68V/S92I/E93P/H95F/R97P/H98G.d3
›7.↳ 1The modified tumor necrosis factor receptor-1 polypeptide of claim 1, comprising an amino acid modification selected from the group consisting of L68V…d2
›10.↳ 1The modified tumor necrosis factor receptor-1 polypeptide of claim 1, comprising an amino acid sequence selected from the group consisting of SEQ ID N…d2
›11.↳ 1A polypeptide complex, comprising two or more copies of the modified tumor necrosis factor receptor-1 polypeptide of claim 1, said copies being covale…d2
›12.↳ 1The modified tumor necrosis factor receptor-1 polypeptide of claim 1, further comprising a chemical modification selected from the group consisting of…d2
›13.↳ 1A cDNA comprising a nucleotide sequence encoding for the modified tumor necrosis factor receptor-1 polypeptide or fragment of claim 1.d2+7
›14.↳ 13The cDNA of claim 13, constructed on basis of the nucleotide sequence of SEQ ID NO: 5 with codon optimization, said codon optimization being performed…d3
›15.↳ 13A vector carrying the cDNA of claim 13.d3+2
›16.↳ 15A bacterial cell or non-human animal cell, transformed with the vector of claim 15.d4+1
›17.↳ 16The cell of claim 16, wherein the cell is E. coli.d5
›20.↳ 13A pharmaceutical composition for treating of a TNF-mediated disease selected from the group consisting of adult respiratory distress syndrome, anorexi…d3+1
›22.↳ 20A method for treating a TNF-mediated disease, comprising administering the pharmaceutical composition of claim 20 to a subject in need thereof.d4
›23.↳ 13multiple · 1, 13A method for producing the modified human tumor necrosis factor receptor-1 polypeptide of claim 1, comprising using the cDNA of claim 13 or a vector c…d3
›18.↳ 1A pharmaceutical formulation, comprising the modified tumor necrosis factor receptor-1 polypeptide of claim 1 and a pharmaceutically acceptable carrie…d2
›19.↳ 1A pharmaceutical composition for treating of a TNF-mediated disease selected from the group consisting of adult respiratory distress syndrome, anorexi…d2+1
›21.↳ 19A method for treating a TNF-mediated disease, comprising administering the pharmaceutical composition of claim 19 to a subject in need thereof.d3
Classifications
38 codesIPC · International Patent Classification
Section A — Human necessities
- A61P1/00
- A61P25/08
- A61P3/04
- A61P19/08
- A61P41/00
- A61P19/02
- A61P1/18
- A61P5/00
- A61K38/17
- A61P11/00
- A61P35/00
- A61P29/00
- A61K31/7088
- A61P25/28
- A61P27/02
- A61P3/10
Section C — Chemistry; metallurgy
- C12N15/70
- C07H21/04
- C07K14/715
- C12N1/21
USPC · US Patent Classification
514/1.4514/19.3514/1.5514/18.3514/16.7514/17.9536/23.5514/20.8514/6.9514/4.8514/44.R435/320.1514/1.1514/17.7514/16.8514/16.6530/350435/252.33
Claim changes
SoonComing soonHow the claims changed between publication and grant
See which claims were amended, added or cancelled during examination, with every added and removed word marked.
AmendedAddedCancelledUnchanged
The published claims of this patent are not paired with the granted ones in what we hold.
File wrapper
⤢ drag to zoom
USPTOApplicanthover for detail · click to open
Pendency
2.0 y
741 days filing → grant
Office actions
1
after a restriction
Responses
2
1 RCE
Interviews
2
examiner interview summaries
Examiner
Schuyler Milton
art unit —
Law firm
Citations: 9 back · 0 forward
See the full prosecution history — every USPTO and applicant action on this file, in order.
Log in to unlockTerm & fees
See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.
Log in to unlockPriority chain
1 priority documents›Priority documents — 1
| Type | Document | Date |
|---|---|---|
| related publication | US 20120277142 A1 | 1 Nov 2012 |
Validity challenges
See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.
Log in to unlockCitations
See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.
Log in to unlock